Ikke- hæmatologiske bivirkninger (ekskl. laboratorieabnormaliteter), som rapporteres hos mindst 5% af patienterne i kliniske studier af Tasigna, er vist i tabel 2.
Non-haematological adverse reactions (excluding laboratory abnormalities) that are reported in at least 5% of the patients in Tasigna clinical studies are shown in Table 2.